.png)
Oncology Updates - Key Oncology News
- Oncofocus Team
- Apr 1
- 2 min read
March 3rd Week, 2026
Regulatory Events
🎯 The US FDA approved Bristol Myers Squibb's nivolumab (anti-PD-1) + doxorubicin + vinblastine + dacarbazine for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III/IV cHL. Additionally, the EC approved nivolumab + brentuximab vedotin for the treatment of children 5 years of age and older, adolescents, and adults up to 30 years of age with R/R cHL after one prior line of therapy. (Ref 1)
❓ How do these approvals impact the current Tx algorithm of cHL?
🎯 The EC granted approval to AstraZeneca’s durvalumab (anti-PD-L1) + standard-of-care FLOT chemotherapy for the treatment of adult patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. (Ref 2)
❓ What are the clinical outcomes that support this approval?
🎯 Telix Pharmaceuticals Limited completed the resubmission of an NDA to the US FDA for TLX101-Px (Floretyrosine F 18 or 18F-FET; PET imaging agent) for the characterization of recurrent or progressive glioma from treatment related changes in both adult and pediatric patients. (Ref 3)
❓ Who are the other key players in the PET imaging agent space?
Special Designations
⭐ The US FDA granted the orphan drug designation to CRISM Therapeutics' irinotecan for the treatment of malignant glioma. (Ref 4)
❓ What are the key unmet medical needs of this indication?
⭐ The US FDA granted the fast track designation to ILDONG Pharmaceutical Company’s venadaparib (PARP inhibitor) for the treatment of gastric cancer. (Ref 5)
❓ Which are the key promising assets in the gastric cancer landscape?
⭐ The US FDA granted the fast track designation to Remix Therapeutics' REM-422 (MYB mRNA degrader) for the treatment of patients with recurrent, metastatic or unresectable adenoid cystic carcinoma (ACC) whose tumors express MYB transcripts containing a poison exon. (Ref 6)
❓ How do the outcomes of this regimen compare against the current SOC?
Deals And Collaborations
🤝 Voro Therapeutics signed a research collaboration with Daiichi Sankyo US through its Daiichi Sankyo Research Institute San Diego, for the development of masked ADC candidates directed against a selected oncology target. (Ref 7)
❓ Which are the key ADCs currently in Daiichi’s Oncology portfolio?
To know answers to these questions and for additional insights, write to us at support@oncofocus.com.
🌐 References:
Comments